Introduction: The aim of this study was to evaluate the prevalence and clinical features of incidental bladder cancer (BC) diagnosis, with special emphasis on possible associations between incidental diagnosis and primary disease stage or grade. Methods: We retrospectively included 501 consecutive patients who underwent transurethral resection of bladder tumor and were diagnosed with primary urothelial carcinoma of the bladder between January 2013 and February 2021 in a university hospital. The type of diagnosis (incidental or nonincidental), patient baseline characteristics and primary stage and grade were studied for interdependencies. Results: 28.5% of all patients and 19.8% of high grade (HG) BC patients had been diagnosed incidentally, most commonly with ultrasound. Incidental diagnosis was associated with lower primary stage and grade of the disease. Most importantly, on multivariable analysis, which included baseline patient characteristics and type of diagnosis, in the subgroup of HG BC patients, muscle-invasive BC (MIBC) or metastatic disease was three times less likely to be diagnosed incidentally than non-MIBC (odds ratio: 0.31, 95% confidence interval: 0.14–0.71, p = 0.006). Conclusions: The study is first to demonstrate that incidental diagnosis of HG BC may be surprisingly prevalent and associated with lower rates of muscle invasion or metastatic disease.

1.
Ferlay
J
,
Ervik
M
,
Lam
F
,
Colombet
M
,
Mery
L
,
Pineros
M
,
Cancer today (powered by GLOBOCAN 2018). IARC CancerBase No. 15
;
2021
. Available from: https://publications.iarc.fr/577.
2.
Abdollah
F
,
Gandaglia
G
,
Thuret
R
,
Schmitges
J
,
Thian
Z
,
Jeldres
C
,
Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis
.
Cancer Epidemiol
.
2013
;
37
(
3
):
219
25
.
3.
Theriault
GP
,
Tremblay
CG
,
Armstrong
BG
.
Bladder cancer screening among primary aluminum production workers in Quebec
.
J Occup Med
.
1990
;
32
(
9
):
869
72
.
4.
Ward
E
,
Halperin
W
,
Thun
M
,
Grossman
HB
,
Fink
B
,
Koss
L
,
Screening workers exposed to 4,4′-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy
.
J Occup Med
.
1990
;
32
(
9
):
865
8
. .
5.
Marsh
GM
,
Cassidy
LD
.
The Drake health registry study: findings from fifteen years of continuous bladder cancer screening
.
Am J Ind Med
.
2003
;
43
(
2
):
142
8
. .
6.
Pesch
B
,
Taeger
D
,
Johnen
G
,
Gawrych
K
,
Bonberg
N
,
Schwentner
C
,
Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines
.
Int Arch Occup Environ Health
.
2014
;
87
(
7
):
715
24
.
7.
Taiwo
OA
,
Slade
MD
,
Cantley
LF
,
Tessier-Sherman
B
,
Galusha
D
,
Kirsche
SR
,
Bladder cancer screening in aluminum smelter workers
.
J Occup Environ Med
.
2015
;
57
(
4
):
421
7
.
8.
Britton
JP
,
Dowell
AC
,
Whelan
P
,
Harris
CM
.
A community study of bladder cancer screening by the detection of occult urinary bleeding
.
J Urol
.
1992
;
148
(
3
):
788
90
. .
9.
Messing
EM
,
Madeb
R
,
Young
T
,
Gilchrist
KW
,
Bram
L
,
Greenberg
EB
,
Long-term outcome of hematuria home screening for bladder cancer in men
.
Cancer
.
2006
;
107
(
9
):
2173
9
.
10.
Raina
R
,
Pahlajani
G
,
Ponsky
LE
,
Agarwal
A
,
Zippe
CD
.
The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22
.
BJU Int
.
2008
;
102
(
3
):
297
300
. .
11.
Roobol
MJ
,
Bangma
CH
,
el Bouazzaoui
S
,
Franken-Raab
CG
,
Zwarthoff
EC
.
Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)
.
Urol Oncol
.
2010
;
28
(
6
):
686
90
. .
12.
Steiner
H
,
Bergmeister
M
,
Verdorfer
I
,
Granig
T
,
Mikuz
G
,
Bartsch
G
,
Early results of bladder-cancer screening in a high-risk population of heavy smokers
.
BJU Int
.
2008
;
102
(
3
):
291
6
.
13.
Starke
N
,
Singla
N
,
Haddad
A
,
Lotan
Y
.
Long-term outcomes in a high-risk bladder cancer screening cohort
.
BJU Int
.
2016
;
117
(
4
):
611
7
. .
14.
Poletajew
S
,
Biernacki
R
,
Buraczyński
P
,
Chojnacki
J
,
Czarniecki
S
,
Gajewska
D
,
Stage of bladder cancer in Central Europe: polish perspective
.
Neoplasma
.
2016
;
63
(
4
):
642
7
.
15.
Price
SJ
,
Shephard
EA
,
Stapley
SA
,
Barraclough
K
,
Hamilton
WT
.
Non-visible versus visible haematuria and bladder cancer risk: a study of electronic records in primary care
.
Br J Gen Pract
.
2014
;
64
(
626
):
e584
9
. .
16.
Skrzypczyk
MA
,
Grothuss
G
,
Dobruch
J
,
Chłosta
P
,
Borówka
A
.
Bladder cancer in Poland
.
Postępy Nauk Med
.
2012
;
25
(
4
):
311
9
.
17.
Mielczarek
Ł
,
Zapała
P
,
Krajewski
W
,
Nowak
Ł
,
Bajkowski
M
,
Szost
P
,
Diagnostic and treatment delays among patients with primary bladder cancer in Poland: a survey study
.
Cent European J Urol
.
2020
;
73
(
2
):
152
9
.
18.
Brierley
JD
,
Gospodarowicz
MK
,
Wittekind
C
.
TNM classification of malignant tumours
. 8th ed.
Wiley-Blackwell: s.n.
;
2016
.
19.
Humphrey
PA
,
Moch
H
,
Cubilla
AL
,
Ulbright
TM
,
Reuter
VE
.
The 2016 WHO classification of tumours of the urinary system
.
Eur Urol
.
2016
;
70
(
1
):
106
19
.
20.
Soukup
V
,
Čapoun
O
,
Cohen
D
,
Hernandez
V
,
Babjuk
M
,
Burger
M
,
Prognostic performance and reproducibility of the 1973 and 2004/2016 WHO grading classification systems in non-muscle-invasive bladder cancer: a European association of urology non-muscle invasive bladder cancer guidelines panel systematic review
.
Eur Urol
.
2017
;
72
(
5
):
801
13
.
21.
Struck
JP
,
Hennig
MJP
,
Hupe
MC
,
Moharam
N
,
Paffenholz
P
,
Nestler
T
,
Discrepancy between German S3 guideline recommendations and daily urologic practice in the management of nonmuscle invasive bladder cancer: results of a binational survey
.
Urol Int
.
2021
. .
22.
Totaro
A
,
Pinto
F
,
Brescia
A
,
Racioppi
M
,
Cappa
E
,
D’Agostino
D
,
Imaging in bladder cancer: present role and future perspectives
.
Urol Int
.
2010
;
85
(
4
):
373
80
.
23.
Loeb
S
,
Bjurlin
MA
,
Nicholson
J
,
Tammela
TL
,
Penson
DF
,
Carter
HB
,
Overdiagnosis and overtreatment of prostate cancer
.
Eur Urol
.
2014
;
65
(
6
):
1046
55
.
24.
van den Bosch
S
,
Witjes
JA
.
Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review
.
Eur Urol
.
2011
;
60
(
3
):
493
500
.
25.
Nuhn
P
,
May
M
,
Sun
M
,
Fritsche
HM
,
Brookman-May
S
,
Buchner
A
,
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder
.
Eur Urol
.
2012
;
61
(
1
):
58
64
.
26.
Lei
AQ
,
Cheng
L
,
Pan
CX
.
Current treatment of metastatic bladder cancer and future directions
.
Expert Rev Anticancer Ther
.
2011
;
11
(
12
):
1851
62
. .
27.
Hurle
R
,
Pasini
L
,
Lazzeri
M
,
Colombo
P
,
Buffi
NM
,
Lughezzani
G
,
Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the bladder cancer Italian active surveillance (BIAS) project
.
BJU Int
.
2016
;
118
(
6
):
935
9
.
28.
Liberman
D
,
Mehus
B
,
Elliott
SP
.
Urinary adverse effects of pelvic radiotherapy
.
Transl Androl Urol
.
2014
;
3
(
2
):
186
95
. .
29.
Shariat
SF
,
Sfakianos
JP
,
Droller
MJ
,
Karakiewicz
PI
,
Meryn
S
,
Bochner
BH
.
The effect of age and gender on bladder cancer: a critical review of the literature
.
BJU Int
.
2010
;
105
(
3
):
300
8
. .
30.
Dobruch
J
,
Daneshmand
S
,
Fisch
M
,
Lotan
Y
,
Noon
AP
,
Resnick
MJ
,
Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes
.
Eur Urol
.
2016
;
69
(
2
):
300
10
.
31.
Barbosa
ALA
,
Vermeulen
SHHM
,
Aben
KK
,
Grotenhuis
AJ
,
Vrieling
A
,
Kiemeney
LA
.
Smoking intensity and bladder cancer aggressiveness at diagnosis
.
PLoS One
.
2018
;
13
(
3
):
e0194039
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.